Your session is about to expire
← Back to Search
Nivolumab + Chemotherapy +/- Radiation for Lung Cancer (CA209-6K6 Trial)
CA209-6K6 Trial Summary
This trial tests how adding radiation therapy to chemo and immune therapy affects outcomes for lung cancer patients.
CA209-6K6 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCA209-6K6 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CA209-6K6 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or can carry out light work.My lung cancer is at a specific stage and I am eligible for surgery aimed at curing it.I do not have active infections like TB, hepatitis B, or hepatitis C.I haven't taken strong immune system suppressing drugs in the last 14 days, except for minor exceptions like creams or low-dose steroids.I have had an autoimmune or inflammatory disorder but no active diverticulitis in the last 3 months.I am not pregnant or breastfeeding and agree to use birth control during and up to 90 days after treatment.I haven't received any cancer treatment in the last 30 days.I have another type of cancer, but it's not active.You have had a bad reaction to nivolumab or any of its ingredients in the past.I am older than 18 years.My lung tumor can be treated with targeted radiation therapy.You have a disease that can be measured using a specific method called RECIST v1.1.I have a history of lung conditions like interstitial lung disease or pneumonitis.I have previously received immunotherapy.I have moderate to severe nerve damage.My organs and bone marrow are functioning well.I have not received any treatment for my lung cancer.You have had an organ transplant from someone else.
- Group 1: Nivolumab + Platinum Doublet Chemotherapy
- Group 2: Nivolumab + Platinum Doublet Chemotherapy + SBRT (8gy x 3)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants is the research team enrolling in this experiment?
"Correct. Clinicaltrials.gov information reveals that this medical trial, which was introduced on January 17th 2023, is still actively enrolling patients. There are 52 participants needed from 1 specific site."
Has the federal government sanctioned Nivolumab coupled with Platinum Doublet Chemotherapy and SBRT (8gy x 3)?
"The safety of Nivolumab + Platinum Doublet Chemotherapy + SBRT (8gy x 3) was assessed as a 2 since this is still in Phase 2, with no efficacy data but some existing information on its safety."
Are there vacancies that participants can fill in this clinical trial?
"Correct. Clinicaltrials.gov confirms this clinical trial is currently recruiting suitable participants, the first posting being made on 17th January 2023 and most recently updated 27th December 2022. 52 people are required from one clinic centre for participation in the study."
Share this study with friends
Copy Link
Messenger